The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global oligonucleotide synthesis market reached a value of US$ 2.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2027, exhibiting a CAGR of 12.71% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Oligonucleotide synthesis is a chemical process wherein short fragments of nucleic acids are linked to each other for forming desired sequenced products. It can be customized by researchers according to the application and their requirements. It is used as primers and probes in recombinant DNA technologies to develop monoclonal antibodies. It is also utilized in biological, medical, forensic, and clinical applications for gene expression, cloning, molecular diagnostics, and genetic disease screening. Moreover, it is gaining traction in therapeutics practices for several drugs on account of the introduction of automated reactor platforms, which provide access to oligonucleotides at reasonable prices.
With the increasing cases of coronavirus disease (COVID-19) and the urgency for a potential treatment, new generations of oligonucleotide drugs, including mRNA and DNA vaccines, are currently under development. Apart from this, the growing incidences of cancer and other chronic illnesses have resulted in the rising demand for novel diagnostics, which is influencing the need for oligonucleotide synthesis to help develop effective therapies and diagnostic techniques. The increasing geriatric population and demand for personalized medicines are also bolstering the market growth. Additionally, with advances in purification and quality control technologies, the overall cost of oligonucleotide techniques can be decreased while substantially increasing quality and yield. This is promoting the application of oligonucleotide synthesis in a range of available modifications. Apart from this, several oligonucleotide-based therapies are in different stages of clinical trials. This is anticipated to propel the demand for oligonucleotide synthesis to treat viral infections, rare genetic disorders, and neuromuscular conditions.
IMARC Group provides an analysis of the key trends in each sub-segment of the global oligonucleotide synthesis market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end use.
Breakup by Product:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Biolegio B.V., Bio-Synthesis Inc, Eurofins Genomics, GenScript, Horizon Discovery Ltd, Integrated DNA Technologies Inc (Danaher Corporation), Kaneka Eurogentec S.A. (Kaneka Corporation), LGC Limited, Nitto Denko Avecia Inc (Nitto Denko Corporation) and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End Use, Region|
|Region Covered||North America, Asia Pacific, Europe, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, China, Japan, India, South Korea, Australia, Indonesia, Germany, France, United Kingdom, Italy, Spain, Russia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Biolegio B.V., Bio-Synthesis Inc, Eurofins Genomics, GenScript, Horizon Discovery Ltd, Integrated DNA Technologies Inc (Danaher Corporation), Kaneka Eurogentec S.A. (Kaneka Corporation), LGC Limited, Nitto Denko Avecia Inc (Nitto Denko Corporation) and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global oligonucleotide synthesis market was valued at US$ 2.4 Billion in 2021.
We expect the global oligonucleotide synthesis market to exhibit a CAGR of 12.71% during 2022-2027.
The rising incidences of cancer and other chronic ailments, coupled with the growing demand for oligonucleotide synthesis for developing effective therapies and diagnostic techniques, are primarily driving the global oligonucleotide synthesis market.
The sudden outbreak of the COVID-19 pandemic has led to the rising demand for oligonucleotide drugs, such as mRNA and DNA vaccines, as immunity booster against the coronavirus infection.
Based on the product, the global oligonucleotide synthesis market can be segmented into synthesized oligonucleotide products, reagents, equipment, and services. Currently, synthesized oligonucleotide products hold the majority of the total market share.
Based on the application, the global oligonucleotide synthesis market has been divided into PCR primers, PCR assays and panels, sequencing, DNA microarrays, Fluorescence In-Situ Hybridization (FISH), antisense oligonucleotides, and others. Among these, PCR primers currently exhibit a clear dominance in the market.
Based on the end use, the global oligonucleotide synthesis market can be categorized into pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, and academic research institutes. Currently, academic research institutes account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global oligonucleotide synthesis market include Agilent Technologies Inc., Biolegio B.V., Bio-Synthesis Inc, Eurofins Genomics, GenScript, Horizon Discovery Ltd, Integrated DNA Technologies Inc (Danaher Corporation), Kaneka Eurogentec S.A. (Kaneka Corporation), LGC Limited, Nitto Denko Avecia Inc (Nitto Denko Corporation), and Thermo Fisher Scientific Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at